BMY

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Bristol-Myers Squibb (BMY) continues to draw attention as investors weigh its current share price of US$54.95 against recent share performance and fundamentals, including revenue of US$48.5b and net income of US$7.3b. See our latest analysis for Bristol-Myers Squibb. The recent 7 day share price return fell 7.58% and the 90 day share price return is down 10.24%, yet the 1 year total shareholder return of 18.25% points to momentum that has been positive over a longer window. If you are comparing Bristol-Myers Squibb with other healthcare opportunities, it could be a helpful moment to scan a wider field of 40 healthcare AI stocks So with earnings contracting and the stock trading at US$54.95 alongside an indicated intrinsic discount, is Bristol-Myers Squibb offering you a mispriced opportunity, or is the market already factoring in its future growth potential? At a last close of $54.95 versus a narrative fair value of $62.96, Bristol-Myers Squibb is framed as undervalued, with that gap hinging on specific forecasts for revenue, margins and valuation multiples. Read the complete narrative. Want to see how shrinking revenue and rising margins still support a higher fair value? The narrative hangs on a richer profit profile and a higher future earnings multiple. Curious what kind of earnings power that implies by the end of the decade. Result: Fair Value of $62.96 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that upside story can be shaken if upcoming patent expiries on key drugs or tougher pricing and regulatory pressure hit revenue and margins harder than expected. Find out about the key risks to this Bristol-Myers Squibb narrative. While the narrative fair value suggests upside, the simple P/E comparison is less generous. Bristol-Myers Squibb trades on a P/E of 15.4x, in line with the US pharmaceuticals average of 15.4x, but below the peer average of 26.7x and under its fair ratio of 18.7x. That mix hints at some room for rerating, yet also a risk that the market is already cautious. Which signal do you treat as more important? See what the numbers say about this price — find out in our valuation breakdown. Balanced or conflicted by...

Shares of Revolution Medicines RVMD were rising in pre-market today after the company reported full results from the phase III RASolute 302 study, which evaluated lead candidate daraxonrasib in previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). These findings were also presented at the 2026 ASCO Annual Meeting yesterday and simultaneously published in the New England Journal of Medicine. Though Revolution Medicines previously reported in April that the study met all primary and secondary endpoints based on interim analysis, the latest findings provide a more comprehensive look at the drug’s clinical benefit. The study enrolled a broad patient population, including those with diverse RAS mutations, particularly G12 variants, as well as those without identifiable RAS mutations. Participants were randomized to receive either 300 mg of oral daraxonrasib once daily or standard-of-care cytotoxic chemotherapy delivered intravenously. The primary endpoints included overall survival (OS) and progression-free survival (PFS) in patients with RAS G12-mutant tumors, while key secondary endpoints assessed these outcomes in the overall study population. Across the RAS G12 population, daraxonrasib reduced the risk of death by 60% compared with standard chemotherapy and achieved a median OS of 13.2 months compared to 6.6 months for chemotherapy. The drug also demonstrated a significant benefit on PFS, with median PFS improving to 7.3 months from 3.5 months with chemotherapy. Similar benefits were seen across the overall study population. Daraxonrasib reduced the risk of death by 60% and improved median OS to 13.2 months compared with 6.7 months for chemotherapy. Median PFS stood at 7.2 months for daraxonrasib versus 3.6 months with chemotherapy. The drug was generally well-tolerated and demonstrated a manageable safety profile. Management noted that patients receiving daraxonrasib experienced meaningful improvements in patient-reported outcomes, including significant delays in the deterioration of cancer-related pain, overall global health status and quality of life. Per Revolution Medicines, these findings strengthen daraxonrasib's potential to become a new treatment option for previously treated metastatic PDAC, a setting where effective therapies remain limited. Based on the above data, the company intends to advance regulatory submission...

Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, marking a 13.6% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation. Is now the time to buy Bristol-Myers Squibb, or should you be careful about including it in your portfolio? Check out our in-depth research report to see what our analysts have to say, it’s free. We’re glad investors have benefited from the price increase, but we're cautious about Bristol-Myers Squibb. Here are three reasons why BMY doesn't excite us and a stock we'd rather own. A company’s long-term sales performance can indicate its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Regrettably, Bristol-Myers Squibb’s sales grew at a tepid 1.4% compounded annual growth rate over the last five years. This was below our standards. Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite. Over the next 12 months, sell-side analysts expect Bristol-Myers Squibb’s revenue to drop by 4%, a decrease from its 1.4% annualized growth for the past five years. This projection is underwhelming and suggests its products and services will face some demand challenges. Analyzing the long-term change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions. Sadly for Bristol-Myers Squibb, its EPS declined by 1.7% annually over the last five years while its revenue grew by 1.4%. This tells us the company became less profitable on a per-share basis as it expanded. Bristol-Myers Squibb’s business quality ultimately falls short of our standards. With its shares outperforming the market lately, the stock trades at 9.2× forward P/E (or $55.77 per share). This valuation is reasonable, but the company’s shakier fundamentals present too much downside risk. We're pretty confident there are more exciting stocks to buy at the moment. We’d suggest looking at the most dominant software business in the world. ONE MORE THING: Top 6 Stocks...

Dr. Reddy's Laboratories Limited RDY reported fourth-quarter fiscal 2026 adjusted earnings of 6 cents per American Depositary Share (ADS), which missed the Zacks Consensus Estimate of 9 cents. The company reported earnings of 18 cents per ADS in the year-ago quarter. Revenues declined 12% year over year to $801 million, missing the Zacks Consensus Estimate of $866 million, primarily due to a year-over-year decline in global generics revenues. Dr. Reddy’s shares lost 5.2% on Tuesday, likely because the dismal fiscal fourth-quarter results disappointed investors. Dr. Reddy’s reported revenues under three segments — Global Generics, Pharmaceutical Services & Active Ingredients (PSAI) and Others. Global Generics revenues totaled INR 65.8 billion, down 13% year over year. The decrease was mainly due to lower North America generics sales, partly offset by broad-based growth across key markets supported by favorable foreign exchange movements. Dr. Reddy’s launched seven new products in North America during the reported quarter. However, revenues in the North America segment declined 51%, largely due to lower lenalidomide sales and a one-time Shelf Stock Adjustment (SSA) of INR 4.5 billion related to the product. As of March 31, 2026, a total of 77 generic filings were pending approval from the FDA, comprising 75 abbreviated new drug applications (ANDAs) and two new drug applications. Of these 75 ANDAs, 43 are Para IVs. Dr. Reddy’s shares have lost 11.3% year to date against the industry’s 1.4% growth. Image Source: Zacks Investment Research PSAI revenues totaled INR 9.12 billion, representing a 5% year-over-year decline, due to lower volume uptake in the active pharmaceutical ingredient (API) business. Revenues in the Others segment totaled INR 0.24 billion, up 79% on a year-over-year basis. Gross margin declined 1,074 basis points year over year to 44.8% in the fourth quarter of fiscal 2026. This was mainly due to lower lenalidomide sales, price erosion in the North America and Europe Generics businesses and the one-time SSA impact. Research and development (R&D) expenses of $58 million were down 25% year over year due to lower development spending in biosimilars following the completion of a significant portion of the investments related to Bristol Myers’ BMY Orencia (abatacept). R&D efforts continue to be focused on complex generics, including peptides and biosi...

Interested in Xenon Pharmaceuticals Inc.? Here are five stocks we like better. Xenon Pharmaceuticals plans to submit an NDA for azetukalner in Q3 2026 after positive Phase 3 focal onset seizure data, with a potential U.S. launch targeted for late 2027 or early 2028. The Phase 3 X-TOLE2 study met its primary endpoint in both dose groups, showing meaningful seizure reductions and a safety profile the company said was consistent with prior studies, supporting its commercialization plans. Xenon ended Q1 with $1.3 billion in cash after a recent financing, which management says should fund operations into 2029 and support its broader epilepsy, depression and early-stage pain pipeline. Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first quarter. On the company’s first-quarter 2026 earnings call, President and Chief Executive Officer Ian Mortimer said the results from the Phase 3 X-TOLE2 study “exceeded our expectations” and reinforced Xenon’s plans to move toward commercialization. Mortimer said the company’s base-case assumption is a standard FDA review period followed by Drug Enforcement Administration scheduling, which would put a potential launch “at the end of 2027 or early 2028.” → Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30% Azetukalner, also referred to as AZK, is a Kv7 potassium channel opener being developed for epilepsy and depression. Xenon is also studying the drug in primary generalized tonic-clonic seizures, major depressive disorder and bipolar depression. Mortimer said the X-TOLE2 study in focal onset seizures demonstrated, to the company’s knowledge, “the highest placebo-adjusted median percent change in monthly focal seizure frequency ever seen in a pivotal FOS study.” The company presented the data as a late-breaking oral presentation at the American Academy of Neurology annual meeting. → Light Speed Returns: Corning Cashes In on NVIDIA Growth Dr. Chris Kenney, Xenon’s chief medical officer, said the study met its primary endpoint in both the 25 mg and 15 mg azetukalner dose groups compared with placebo. He said the me...

Prothena Corporation PRTA reported first-quarter 2026 adjusted earnings per share (excluding restructuring costs) of 52 cents. The Zacks Consensus Estimate was a loss of 31 cents per share. In the year-ago quarter, the company had incurred a loss of $1.12 per share. The bottom line was boosted by higher revenues resulting from a milestone payment from Novo Nordisk NVO. Revenues totaled $51.1 million compared with $2.8 million in the year-ago quarter. The top line primarily comprises collaboration revenues and milestone payments. First-quarter 2026 revenues were primarily driven by a $50.0 million milestone payment from NVO tied to the ongoing late-stage study of coramitug, along with collaboration revenues from Bristol Myers Squibb BMY related to the partial fulfillment of the company’s phase I study obligations for PRX019. Prothena’s shares have gained 10.1% in the year so far against the industry’s decline of 0.2%. Image Source: Zacks Investment Research Research and development (R&D) expenses decreased 75.2% to $12.6 million from $50.8 million in the prior-year period, primarily driven by lower clinical trial, personnel, manufacturing and consulting expenses. General and administrative (G&A) expenses decreased 28% to $12.7 million from $17.6 million in the year-ago period, mainly due to lower consulting and personnel expenses. As of March 31, 2026, Prothena had $330.3 million in cash, cash equivalents and restricted cash, compared with $308.4 million as of Dec. 31, 2025. The company had no debt at the end of the first quarter. Prothena Corporation plc price-consensus-eps-surprise-chart | Prothena Corporation plc Quote Prothena lowered its guidance for full-year 2026 net cash used in operating and investing activities to $18-$23 million from $50-$55 million. The company now expects to end 2026 with approximately $273 million in cash, cash equivalents and restricted cash at the midpoint, up $18 million from the previous midpoint guidance of $255 million. The improved cash outlook was primarily driven by the milestone payment from Novo Nordisk tied to the advancement of coramitug, partially offset by approximately $15 million used for share repurchases through April 30, 2026, liabilities related to discontinued programs and increased investment in preclinical programs. The updated outlook for net cash used in operating and investing activities is primarily b...

JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate JANX011 Phase 1 study ongoing in healthy volunteers Discontinued development of JANX008 following completion of Phase 1a Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment Strong cash position supporting continued pipeline execution SAN DIEGO, May 07, 2026--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update. "Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic," said David Campbell, Ph.D., President and CEO of Janux. "Our ongoing clinical study with JANX011 has been designed to support our emerging autoimmune disease opportunity." BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS: Clinical & Pipeline Progress JANX007 (PSMA-TRACTr) continues to enroll in its Phase 1b trial in metastatic castration-resistant prostate cancer (mCRPC), with ongoing dose optimization and expansion in taxane-naïve patients. An expansion cohort evaluating JANX007 in combination with darolutamide, an androgen receptor pathway inhibitor, is actively enrolling in taxane-naïve mCRPC. JANX014 (PSMA-TRACTr), a double masked tumor-activated T cell engager, has initiated clinical evaluation. Following the completion of the Phase 1a portion of the study and internal review of the data, the Company has discontinued further clinical development of JANX008 (EGFR-TRACTr) and is prioritizing resources toward other pipeline opportunities. JANX011 (CD19-ARM) is actively enrolling in its Phase 1 clinical trial in healthy volunteers. The Company continues to advance additional TRACTr, TRACIr and ARM programs for potential future development. Strategic Collaborations Janux announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic targeting a validated solid tumor antigen, utilizing Janux’s TRACTr platform. Recently anno...

Cytokinetics, Incorporated CYTK reported a first-quarter 2026 loss of $1.67 per share, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company reported a loss of $1.36 per share. Loss widened year over year due to higher SG&A expenses tied to costs associated with the commercial launch of Myqorzo. Revenues amounted to $19.4 million, up from $1.6 million reported in the year-ago quarter. The top line surpassed the Zacks Consensus Estimate of $7.0 million. The quarter reflected CYTK’s transition into a commercial-stage story, supported by early Myqorzo launch traction and a sizable year-over-year step-up in total revenues. Cytokinetics’ shares have surged 21.3% year to date against the industry’s 2.4% decline. Image Source: Zacks Investment Research Net product revenues from Myqorzo were $4.8 million, reflecting approximately nine weeks of U.S. sales following its launch. In December 2025, the FDA approved Myqorzo (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Through April, management noted that patients on therapy expanded to roughly 1,100, pointing to accelerating early demand. Commercial momentum is being paired with expanding regulatory and geographic scope. Myqorzo received European Commission approval for adults with symptomatic obstructive HCM, and Cytokinetics indicated it is moving toward its first European commercial launch in Germany in the second quarter of 2026. Beyond product sales, quarterly revenues included $11.9 million tied to a milestone under the license agreement with Bayer BAYRY, associated with the first commercial sale of Myqorzo in the United States. Collaboration revenues amounted to $2.6 million, up from $1.6 million in the year-ago quarter. Operating expenses rose in line with a company funding its first launch. Selling, general and administrative expense climbed to $104.9 million from $57.4 million a year ago, driven by external costs related to Myqorzo commercialization, the U.S. sales force buildout and higher personnel-related costs, including stock-based compensation. Research and development expense was $95.5 million, down from $98.3 million in the prior-year quarter. Management attributed the modest decline to higher clinical trial activity last year, partially offset by increased personnel-related costs in 2026. CYTK ended the first quarter with approximately...

Pfizer faces a looming patent cliff and evaporating demand for its Covid drugs. Quarterly revenue rose 2% on an operational basis to $14.5 billion and topped analysts’ calls for $13.8 billion. Excluding contributions from Pfizer’s Covid franchise, which includes its Comirnaty vaccine and Paxlovid antiviral pill, revenue grew 7% on an operational basis.

Pfizer PFE reported first-quarter 2026 adjusted earnings per share of 75 cents, which beat the Zacks Consensus Estimate of 71 cents per share. Earnings declined 18% year over year. Revenues came in at $14.45 billion, up 5% from the year-ago quarter on a reported basis and 2% on an operational basis. Total revenues beat the Zacks Consensus Estimate of $13.82 billion. International revenues declined 1% on an operational basis to $5.72 billion. U.S. revenues rose 4% to $8.73 billion. Pfizer reports its revenues under three broad sub-segments of its Biopharma operating segment — Primary Care, Specialty Care and Oncology. In first-quarter 2026, Pfizer created a new Hospital and Biosimilars Division within its Biopharma segment, moving certain off-patent brands, generic sterile injectables, and biosimilars out of Specialty Care and Oncology. Sales of the Primary Care segment declined 6% operationally to $5.54 billion. The Specialty Care unit recorded sales of $2.94 billion, up 8%. Sales of Oncology rose 7% to $3.83 billion. Sales in the Hospital and Biosimilars segment rose 10% to $1.85 billion in the first quarter. In Primary Care, alliance revenues and direct sales from partner Bristol-Myers BMY for Eliquis rose 8% to $2.17 billion as higher demand trends globally were partially offset by price and generic erosion in some ex-U.S. markets. Alliance revenues beat the Zacks Consensus Estimate of $1.85 billion. Global Prevnar family revenues declined 1% to $1.69 billion. Prevnar revenues beat the Zacks Consensus Estimate of $1.63 billion. Prevnar sales declined 10% in the United States but rose 21% in international markets. Direct sales and alliance revenues from partner BioNTech BNTX for the COVID vaccine, Comirnaty, were $232 million in the quarter, down 59% year over year due to narrower COVID-19 vaccine recommendations in the United States that reduced Comirnaty’s eligible patient population and lower contractual deliveries and vaccination rates in international markets. Comirnaty sales missed the Zacks Consensus Estimate of $411 million. Paxlovid revenues were $186 million in the quarter, down 63% year over year due to lower infection rates, which hurt demand trends globally and lower international government purchases. Paxlovid revenues also missed the Zacks Consensus Estimate of $296 million. Nurtec ODT/Vydura contributed $353 million in the quarter, up 41% y...

The first-quarter 2026 reporting cycle of the Medical sector is in full swing. The sector primarily comprises pharma/biotech and medical device companies. Many pharma giants, like AbbVie and Eli Lilly, as well as large-cap biotechs like Bristol Myers and GSK, reported earnings last week. Results for many of these companies were strong, as they crushed estimates for both earnings and sales. While Lilly and AbbVie raised their previously issued guidance, Bristol Myers and GSK reiterated their outlook. The Earnings Trends report indicates that, as of April 29, 36% of the companies in the Medical sector — representing more than 45% of the sector’s market capitalization — have reported quarterly earnings. While about 86% of participants beat on earnings, more than 90% outperformed revenues. Earnings rose more than 4% year over year, while revenues increased nearly 7%. Overall, first-quarter earnings are expected to fall by about 8% year over year, while sales are expected to rise by nearly 7%. While most companies in the sector have reported earnings, some companies have yet to report. Out of them, we have highlighted five biotech companies — ANI Pharmaceuticals ANIP, Cytokinetics CYTK, Novavax NVAX, Revolution Medicines RVMD and Sarepta Therapeutics SRPT — that seem poised to deliver a beat in their upcoming quarterly results. Earnings ESP is our proprietary methodology for determining the stocks with the best chance to deliver an earnings surprise. It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate. According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener. Our research shows that the chance of an earnings surprise for stocks with this combination is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. ANIP is a commercial-stage company that develops, manufactures and markets therapeutics across rare diseases and generics. The company has an Earnings ESP of +7.81% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for first-quarter earnings is pegged at $1.28 per share. ANI Pharmaceuticals beat on...

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novavax, Inc. (NVAX) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research